In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.

In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.

We sought to determine the predictive value of in situ mRNA measurement compared to traditional methods on a cohort of trastuzumab-treated metastatic breast cancer patients.A tissue microarray composed of 149, classified as HER2-positive, metastatic breast cancers treated with various trastuzumab-co...

Full description

Bibliographic Details
Main Authors: Maria Vassilakopoulou, Taiwo Togun, Urania Dafni, Huan Cheng, Jennifer Bordeaux, Veronique M Neumeister, Mattheos Bobos, George Pentheroudakis, Dimosthenis V Skarlos, Dimitrios Pectasides, Vassiliki Kotoula, George Fountzilas, David L Rimm, Amanda Psyrri
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4072595?pdf=render

Internet

http://europepmc.org/articles/PMC4072595?pdf=render

Similar Items